UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/016,604	12/07/2001	Pablo D. Garcia	PP016466.0002	6543
27476 7590 11/14/2007 NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338			EXAMINER	
			HUMPHREY, LOUISE WANG ZHIYING	
	P.O. BOX 8097 Emeryville, CA 94662-8097		ART UNIT	PAPER NUMBER
	,		1648	
			MAIL DATE	DELIVERY MODE
			11/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/016,604	GARCIA ET AL.
Office Action Summary	Examiner	Art Unit
	Louise Humphrey, Ph.D.	1648
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA 136(a). In no event, however, may a reply will apply and will expire SIX (6) MONTHS e, cause the application to become ABAN	TION. be timely filed from the mailing date of this communication. DONED (35 U.S.C. § 133).
Status		
 Responsive to communication(s) filed on 13 S This action is FINAL. Since this application is in condition for alloware closed in accordance with the practice under the second secon	s action is non-final. ince except for formal matters	·
Disposition of Claims		
4) ⊠ Claim(s) <u>1,3-6,10,13-15 and 39-113</u> is/are per 4a) Of the above claim(s) is/are withdra 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1,3-6,10,13-15 and 39-113</u> are subjected in the subject of the su	wn from consideration.	n requirement.
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 10.	cepted or b) objected to by drawing(s) be held in abeyance ction is required if the drawing(s)	. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		•
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat * See the attached detailed Office action for a list	ts have been received. ts have been received in App prity documents have been re tu (PCT Rule 17.2(a)).	lication No ceived in this National Stage
Attackersesta		
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/N	nmary (PTO-413) Mail Date mal Patent Application

Application/Control Number: 10/016,604

Art Unit: 1648

DETAILED ACTION

Page 2

This restriction is in response to the amendment filed on 13 September 2007.

Claims 2, 7-9, 12 and 16-38 are cancelled. New claims 39-113 are added. Claims 1,3-6,10,13-15 and 39-113 are pending. The amended and new claims present new multiple inventions, which necessitate a supplementary restriction as follows:

Restriction to Single Sequence Election

Note that this is <u>not a species election</u> and is <u>separate from a group election</u>.

Claims 1,3-6,10,13-15 and 39-113 specifically claim multiple nucleotide sequences, which are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. §121. Each such sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. §121 and 37 CFR 1.141 *et seq* (See MPEP §803.04). Each sequence is not considered to be a proper member of a Markush group. See M.P.E.P. § 803.02. *In re Harnish*, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility, and (2) share a substantial structural feature disclosed as being essential to that utility. As such, sequences in each of claims 1,3-6,10,13-15 and 39-113 are not considered to constitute a proper genus/Markush, and are therefore subject to additional restriction.

Application/Control Number: 10/016,604

Art Unit: 1648

Furthermore, a search of more than one (1) of the sequences present in these claims presents an undue burden on the Patent and Trademark Office due to the complex nature of the search in terms of computer time needed to perform the search and the subsequent analysis of the search results by the examiner. Each of the SEQ ID NO's is a unique and separately patentable sequence, requiring a non-coextensive search for the prior art.

In view of the foregoing, one (1) sequence is considered to be a reasonable number of sequences for examination. Accordingly, applicants must further elect ONE nucleotide sequence, identified by ONE SEQ ID NO., which if determined to be patentable, would also be patentably distinct from other sequences. Failure to elect a specific sequence will be considered to be non-responsive reply.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Louise Humphrey, Ph.D. whose telephone number is 571-272-5543. The examiner can normally be reached on Mon-Thu, 9:00 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Louise Humphrey, Ph.D. Assistant Patent Examiner

09 November 2007

Jeffrey Parkin, Ph.D Primary Patent Examiner